• POS7 COST-EFFECTIVENESS OF TERIPARATIDE (FORTEO) IN THE PREVENTION OF OSTEOPOROTIC FRACTURES AMONG MEN AND POSTMENOPAUSAL WOMEN IN AUSTRALIA

    May 1, 2004, 00:00

  • POS1 THE INFLUENCE OF BONE MINERAL DENSITY TESTING ON THE INITIATION OF AN OSTEOPOROSIS-RELATED PHARMACOTHERAPY- A POPULATION-BASED ANALYSIS

    May 1, 2004, 00:00

  • CN4 COST-EFFECTIVENESS (CE) ANALYSIS OF INTERFERON-ALPHA IN HIGH-RISK MELANOMA PATIENTS

    May 1, 2004, 00:00

  • PIN24 ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE SETTINGS FOR PATIENTS DIAGNOSED WITH INFLUENZA, 1997-2001

    May 1, 2004, 00:00

  • PAA15 INVESTIGATION OF THE DETERMINANTS OF ADHERENCE IN ASTHMA USING Q METHODOLOGY

    May 1, 2004, 00:00

  • PUK9 ECONOMIC IMPACT OF EPOETIN ALFA (EPO) TREATMENT AMONG NON-DIALYSIS CHRONIC KIDNEY DISEASE (NDCKD) PATIENTS WITH ANEMIA

    May 1, 2004, 00:00

  • PCN9 COST EFFECTIVENESS OF ADDING BISPHOSPHONATES TO THE NON-SURGICAL ANDROGEN DEPRIVATION THERAPY FOR FRACTURE REDUCTION IN PATIENTS WITH NONMETASTATIC PROSTATE CANCER

    May 1, 2004, 00:00

  • PAA12 RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN COST/VISITS) BEFORE AND AFTER INTRODUCTION OF THE NEW TREATMENT GUIDELINES IN ASTHMA (1997) AND ODDS OF BEING ON APPROPRIATE ASTHMA THERAPY USING MULTIVARIATE LOGISTIC REGRESSION

    May 1, 2004, 00:00

  • MH2 IMPACT OF OPEN ACCESS TO ATYPICAL ANTIPSYCHOTICS IN CALIFORNIA MEDICAID

    May 1, 2004, 00:00

  • PMD6 RESOURCE COSTING IN CLINICAL TRIALS

    May 1, 2004, 00:00

  • SC3 FACTORS IMPACTING MAMMOGRAPHY SCREENING IN RURAL AND URBAN AREAS

    May 1, 2004, 00:00

  • POS3 HEALTH CARE UTILIZATION AND EXPENDITURES- A STUDY OF SEVERE OSTEOPOROSIS

    May 1, 2004, 00:00

  • SC1 PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC) SCREENING STRATEGIES

    May 1, 2004, 00:00

  • PAR4 COST-EFFECTIVENESS OF TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS AS FIRST-LINE AGENTS IN RHEUMATOID ARTHRITIS

    May 1, 2004, 00:00

  • PMD24 EXPECTED VALUE OF SYMMETRY OF INFORMATION-A FRAMEWORK FOR ASSESSING THE POTENTIAL VALUE OF INDIVIDUALIZING CARE BASED ON PATIENT PREFERENCES

    May 1, 2004, 00:00

  • PDB20 COST-EFFECTIVENESS OF DULOXETINE VERSUS ROUTINE TREATMENT FOR PAINFUL DIABETIC NEUROPATHY IN A RANDOMIZED TRIAL FROM A SOCIETAL PROSPECTIVE

    May 1, 2004, 00:00

  • PSD2 ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION (ADSD) IN EUROPE-A PRELIMINARY INVESTIGATION

    May 1, 2004, 00:00

  • PMH53 HOSPITALIZATION RATES DURING COMBINATION THERAPY WITH ATYPICAL ANTIPSYCHOTICS IN BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PMH4 ATYPICAL ANTIPSYCHOTIC TREATMENT ADHERENCE AND PERSISTENCE IN A STATE MEDICAID PROGRAM

    May 1, 2004, 00:00

  • PIN18 DIRECT TREATMENT COSTS OF TINEA CAPITIS AMONG THE UNITED STATES PRIVATELY INSURED POPULATION

    May 1, 2004, 00:00

  • PMH44 REMISSION OF PSYCHOTIC SYMPTOMS AND LONG-TERM FUNCTIONAL OUTCOMES IN THE TREATMENT OF SCHIZOPHRENIA IN USUAL CARE

    May 1, 2004, 00:00

  • PMD27 THE APPLICATION OF TWO PRODUCTIVITY INSTRUMENTS AT A LARGE EMPLOYER

    May 1, 2004, 00:00

  • PAR17 CHARACTERIZATION OF THE TREATMENT OF RHEUMATOID ARTHRITIS FOR PATIENTS PRESCRIBED TUMOR NECROSIS FACTOR-ALPHA INHIBITORS

    May 1, 2004, 00:00

  • PCN17 THE HEALTH CARE COST OF SMOKING IN CANADA

    May 1, 2004, 00:00

  • PCV19 GENDER AND STATIN THERAPY COST AND EFFICACY

    May 1, 2004, 00:00

  • PMH62 HOSPITAL UTILIZATION FOLLOWING AN OPEN ACCESS POLICY FOR ATYPICAL ANTIPSYCHOTIC MEDICATIONS FOR PATIENTS WITH SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PCV23 HEALTH CARE AND DRUG UTILIZATION PATTERNS IN PATIENTS RECEIVING LONG TERM THIENOPYRIDINE THERAPY

    May 1, 2004, 00:00

  • PCV41 MEDICATION POSSESSION RATIOS FOR PATIENTS WITH CALCIUM CHANNEL BLOCKERS AND/OR STATINS

    May 1, 2004, 00:00

  • PCV17 A COST-UTILITY ANALYSIS OF LOSARTAN VERSUS ATENOLOL IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION

    May 1, 2004, 00:00

  • DB1 THE IMPACT OF USING EITHER THE FRAMINGHAM OR THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY RISK FORMULAE IN DIABETES HEALTH ECONOMICS MODELING

    May 1, 2004, 00:00

  • PUK2 A COST COMPARISON ANALYSIS OF TWO CLINICALLY UROSELECTIVE ALPHA BLOCKERS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    May 1, 2004, 00:00

  • PDB21 THE IMPACT OF COMMON DIABETIC COMPLICATIONS ON QUALITY OF LIFE

    May 1, 2004, 00:00

  • AR4 THE DEVELOPMENT OF PROPENSITY SCORES FROM ADMINISTRATIVE DATABASES FOR THE ANALYSIS OF THE EFFECTIVENESS OF AN OSTEOARTHRITIS ACADEMIC DETAILING SERVICE ON PRESCRIBING BEHAVIOUR

    May 1, 2004, 00:00

  • CV2 CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS COMPARED TO OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS- AN OBSERVATIONAL STUDY OF A MEDICAID POPULATION

    May 1, 2004, 00:00

  • WORK LOSS AND ACTIVITY IMPAIRMENT DUE TO INFLAMMATORY BOWEL DISEASE

    May 1, 2004, 00:00

  • AR3 REVALIDATION OF THE ORIGINAL CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) INSTRUMENT

    May 1, 2004, 00:00

  • PCV55 DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERCHOLESTEROLAEMIA

    May 1, 2004, 00:00

  • CE1 A FRAMEWORK FOR COSTING RECOMMENDATIONS IN PHARMACOECONOMIC GUIDELINES

    May 1, 2004, 00:00

  • PMH74 COMPARING PSYCHOMETRIC PROPERTIES OF SELF-VERSUS INTERVIEWER-RATED INSTRUMENTS USED IN CLINICAL TRIALS FOR PATIENTS WITH ANXIETY DISORDERS

    May 1, 2004, 00:00

  • PUK11 PATIENT PERSISTENCY WITH MEDICATIONS FOR OVERACTIVE BLADDER

    May 1, 2004, 00:00

  • PNL24 DEVELOPING A COMPUTER ALGORITHM TO IDENTIFY EPILEPSY CASES IN MANAGED CARE ORGANIZATIONS AND ESTIMATE PREVALENCE, INCIDENCE, AND MORTALITY

    May 1, 2004, 00:00

  • PIN16 COST-EFFECTIVENESS OF FOUR ANTIMICROBIAL REGIMENS IN PATIENTS ADMITTED TO THE MEDICAL FLOOR WITH CLASS IV OR V COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 2004, 00:00

  • PMH40 COST-EFFECTIVENESS OF RITALINTM VERSUS ADDERALLTM FOR FIRST-LINE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN

    May 1, 2004, 00:00

  • PE3 COMORBIDITY INFLUENCE INDEX

    May 1, 2004, 00:00

  • PCV43 EVALUATION OF THE ASSOCIATION BETWEEN HEALTH-RELATED UTILITY AND OBESITY IN HOSPITAL TREATED SUBJECTS

    May 1, 2004, 00:00

  • PIN20 BURDEN OF ILLNESS OF BACTERIAL CELLULITIS AND ERYSIPELAS OF THE LEG IN THE NETHERLANDS

    May 1, 2004, 00:00

  • PHP9 RELATIONSHIP BETWEEN PATIENT-REPORTED READINESS, SELF-MANAGEMENT BEHAVIOR, AND HEALTH STATUS IN MANAGED-CARE PATIENTS WITH CHRONIC CONDITIONS

    May 1, 2004, 00:00

  • PCV44 BMI, SELF-REPORTED COMORBIDITIES, AGE, AND GENDER DO NOT EXPLAIN COUNTRY-SPECIFIC DIFFERENCES IN OBESITYRELATED QUALITY OF LIFE

    May 1, 2004, 00:00

  • PHP23 PHARMACEUTICAL PRESCRIPTION- COSTS AND FACTORS OF INFLUENCE

    May 1, 2004, 00:00

  • PAA13 COSTS

    May 1, 2004, 00:00

  • PCN14 AN ECONOMIC EVALUATION OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A US HEALTH CARE PERSPECTIVE

    May 1, 2004, 00:00

  • PHP25 ASSESSMENT OF THE IMPACT OF 'ACADEMIC DETAILING' IN PROMOTING COST-EFFECTIVE GENERIC DRUG PRESCRIPTION AMONG AMBULATORY CARE PHYSICIANS IN WEST VIRGINIA

    May 1, 2004, 00:00

  • PHP3 HANDGUN INJURIES TO CHILDREN AND TEENS RESULTING IN HOSPITALIZATION- CIRCUMSTANCES, RESOURCE USE AND COSTS

    May 1, 2004, 00:00

  • PHP43 THE IMPACT OF PRICE CONTROLS ON PHARMACEUTICAL RD INVESTMENT

    May 1, 2004, 00:00

  • PHP31 POTENTIALLY INAPPROPRIATE PRESCRIBING FOR OLDER VETERANS-WHOS AT RISK?

    May 1, 2004, 00:00

  • PMH65 SECOND SSRIS SWITCHING AND DISCONTINUATION AFTER FLUOXETINE INITIAL THERAPY

    May 1, 2004, 00:00

  • PCV27 HOSPITALIZATION COSTS AND LENGTH OF STAY IN POST-MI PATIENTS WITH HEART FAILURE

    May 1, 2004, 00:00

  • PAR10 IMPROVING THE SENSITIVITY OF PHYSICAL FUNCTION MEASURES IN RHEUMATOID ARTHRITIS- USE OF ITEM RESPONSE THEORY IN PATIENTS TREATED WITH ABATACEPT (CTLA4IG)

    May 1, 2004, 00:00

  • PDB2 COMPARISON OF PIOGLITAZONE WITH OTHER ANTIDIABETIC DRUGS FOR ASSOCIATED INCIDENCE OF LIVER FAILURE- NO EVIDENCE OF INCREASED LIVER FAILURE WITH PIOGLITAZONE

    May 1, 2004, 00:00

  • PMH9 ANALYSIS OF ANTIDEPRESSANT MEDICATION UTILIZATION AND ADHERENCE OF MANAGED CARE PATIENTS ENROLLED IN A MEDICATION ADHERENCE PROGRAM

    May 1, 2004, 00:00

  • PDB6 GENDER DISPARITY IN THE MANAGEMENT OF DYSLIPIDEMIA AMONG TYPE 2 DIABETES PATIENTS IN A MANAGED-CARE SETTING

    May 1, 2004, 00:00

  • PCO2 IMPACT OF ANEMIA ON HOSPITALIZATION AND MORTALITY IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CHRONIC KIDNEY DISEASE

    May 1, 2004, 00:00

  • PDB30 DEVELOPMENT OF A DIABETES RESOURCE CONSUMPTION INDEX (DRCI) USING VETERANS HEALTH ADMINISTRATION DATA

    May 1, 2004, 00:00

  • PCV59 CLINICAL PHARMACIST INVOLVMENT IN COMMUNITY ANTICOAGULATION CONTROL

    May 1, 2004, 00:00

  • PES8 ECONOMIC RESOURCES UTILIZED IN A COHORT OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD)

    May 1, 2004, 00:00

  • PPN7 TRENDS IN MEDICAL USE AND ABUSE OF SUSTAINEDRELEASE OPIOID ANALGESICS- A REVISIT

    May 1, 2004, 00:00

  • PCN21 SHORT-TERM PSYCHOSOCIAL COUNSELING FOR PATIENTS WITH NEWLY-DIAGNOSED PROSTATE CANCER

    May 1, 2004, 00:00

  • PAA5 LOCAL ADVERSE EVENT RATES AND COSTS ASSOCIATED WITH INHALED CORTICOSTEROIDS USE

    May 1, 2004, 00:00

  • PCV33 COST ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM FOR ANTI-OBESITY THERAPY IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PBR1 THE ECONOMIC BURDEN OF ANEMIA IN AN INSURED POPULATION

    May 1, 2004, 00:00

  • RI3 COST-EFFECTIVENESS OF INFLUENZA VACCINE IN 6-24 MONTH OLD CHILDREN

    May 1, 2004, 00:00

  • POS5 ECONOMIC EVALUATION OF SHORT-TERM NON-VERTEBRAL FRACTURE-RELATED COSTS AMONG OSTEOPOROSIS TREATMENTS

    May 1, 2004, 00:00

  • PNL20 UTILIZATION OF IMMUNOMODULATORY DRUG THERAPIES IN MULTIPLE SCLEROSIS (MS) IN NOVA SCOTIA, CANADA 1998-2003

    May 1, 2004, 00:00

  • PIN15 THE COST OF TREATMENT FAILURE IN ACUTE BACTERIAL MAXILLARY SINUSITIS

    May 1, 2004, 00:00

  • PDB1 LOWER INCIDENCE OF MICROVASCULAR EVENTS ASSOCIATED WITH PIOGLITAZONE MONOTHERAPY THAN INSULIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES- A RETROSPECTIVE PROPENSITY SCORE MATCHED COHORT ANALYSIS

    May 1, 2004, 00:00

  • PMH31 COST AND COMORBIDITIES ASSOCIATED WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PIN26 MENINGOCOCCAL VACCINE IN PORTUGAL-A COST-EFFECTIVENESS ANALYSIS

    May 1, 2004, 00:00

  • PAA4 INHALED SALMETEROL UTILIZATION AND ASTHMA PATIENT OUTCOMES IN A GROUP-MODEL MANAGED CARE ORGANIZATION

    May 1, 2004, 00:00

  • PHP12 FACTORS AFFECTING CONSUMER VIEWS REGARDING GENERIC DRUG SUBSTITUTION PRACTICES- AN EFFECTIVE TOOL TO MANAGE HEALTH CARE COST

    May 1, 2004, 00:00

  • PCV34 QUALITY OF LIFE FROM THE MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE FOLLOWING AORTIC VALVE REPLACEMENT SURGERY

    May 1, 2004, 00:00

  • PHP19 COMPARING THE COSTS OF MAIL ORDER AND RETAIL PHARMACY

    May 1, 2004, 00:00

  • PCN1 EPOETIN ALFA AND DARBEPOETIN ALFA ANEMIA TREATMENT OUTCOMES IN CANCER PATIENTS FROM A VA PERSPECTIVE

    May 1, 2004, 00:00

  • PMH50 THE ROLE OF ANTIPARKINSONIAN AGENTS IN SELFREPORTED COGNITIVE IMPAIRMENT AND AKATHISIA DURING THE LONG-TERM TREATMENT OF SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PCV10 THE IMPACT OF ADEQUATE MONITORING OF LIPID LEVELS IN PATIENTS HAVING ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS IN A LOCAL PUBLIC HOSPITAL IN HONG KONG

    May 1, 2004, 00:00

  • PNL6 COMPARISON OF CLINICAL EFFICACY AND COSTEFFECTIVENESS BETWEEN ELETRIPTAN 40MG AND SUMATRIPTAN 100MG IN THE ACUTE TREATMENT OF MIGRAINE

    May 1, 2004, 00:00

  • PSD3 TOTAL HEALTH CARE COSTS FOR BENIGN PROSTATIC HYPERPLASIA PATIENTS ON ALPHA1-BLOCKER TREATMENT IN A MANAGED CARE SETTING

    May 1, 2004, 00:00

  • PNL21 INSOMNIA IN A NATIONAL AMBULATORY CARE SETTING 2001

    May 1, 2004, 00:00

  • PCN24 QUALITY OF LIFE OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS IN A PUBLIC VS. PRIVATE SETTING

    May 1, 2004, 00:00

  • PE1 ASSESSING EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING- DATA FROM AN EFFECTIVENESS STUDY OF ANTIPSYCHOTICS

    May 1, 2004, 00:00

  • PCN8 OUTCOMES AND COSTS OF SURROGATE END-POINTS (SES) AND BIOMARKERS IN PHASE I ONCOLOGY CLINICAL TRIALS

    May 1, 2004, 00:00

  • CE2 PANEL ANALYSIS OF CENSORED MEDICAL COST DATA

    May 1, 2004, 00:00

  • PGI8 A PHARMACOECONOMIC ASSESSMENT OF THE BENEFITS AND COSTS OF MANAGING IMMUNOSUPPRESSION IN POST-LIVER TRANSPLANT PATIENTS-A UNIVERSITY HOSPITAL PERSPECTIVE

    May 1, 2004, 00:00

  • PHP17 RECENT TRENDS IN INPATIENT DRUG COSTS- 2000-2002

    May 1, 2004, 00:00

  • PAA1 MEASURING THE IMPACT OF AN ASTHMA DISEASE MANAGEMENT INTERVENTION ON PHARMACY AND IN-PATIENT SERVICE UTILIZATION IN A MANAGED CARE SETTING

    May 1, 2004, 00:00

  • PAA20 PREFERENCE SCORES FROM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) PATIENTS

    May 1, 2004, 00:00

  • PES16 VALIDATION OF A NEW SELF-ASSESSMENT QUESTIONNAIRE AND THE SKINDEX-29 QUALITY OF LIFE (QOL) INSTRUMENT FOR CHRONIC HAND DERMATITIS (CHHD)- A PILOT STUDY

    May 1, 2004, 00:00

  • PHP28 PATIENT SATISFACTION-PATIENT EDUCATION INTERFACE

    May 1, 2004, 00:00

  • PIN10 OFF-LABEL USE OF PIPERACILLIN/TAZOBACTAM (ZOSYN) IN A PEDIATRIC UNIT

    May 1, 2004, 00:00

  • PIN13 AN ECONOMIC AND CLINICAL ASSESSMENT OF FIRST-LINE MONOTHERAPY IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA WITHIN MANAGED CARE

    May 1, 2004, 00:00

  • PMH18 THE EFFECTS OF OPEN ACCESS ON DRUG THERAPY OUTCOMES FOR PATIENTS WITH BIPOLAR DISORDER IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM

    May 1, 2004, 00:00

  • PMH42 CORRELATIONS BETWEEN PSYCHOPATHOLOGY AND HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN SCHIZOPHRENIA. RESULTS FROM THE SQUARE STUDY

    May 1, 2004, 00:00

  • PCV58 USE OF GPIIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH DRUG-ELUTING STENTS

    May 1, 2004, 00:00

  • PAR8 THE RELATIONSHIP BETWEEN GASTROINTESTINAL SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE IN KOREAN PATIENTS WITH RHEUMATIC DISEASES

    May 1, 2004, 00:00

  • PUK7 A COST EVALUATION OF CYCLOPHOSPHAMIDE PLUS PREDNISONE VERSUS AZATHIOPRINE PLUS PREDNISONE FOR TREATMENT OF LUPUS NEPHRITIS

    May 1, 2004, 00:00

  • PAA11 EFFECTIVENESS AND COST-BENEFIT OF LEUKOTRIENE MODIFIERS IN ADULTS WITH ASTHMA IN THE OHIO MEDICAID POPULATION

    May 1, 2004, 00:00

  • PCV3 USING HEALTH-RISK APPRAISAL DATA FOR ASSESSING PREDICTORS OF HYPERTENSION TREATMENT

    May 1, 2004, 00:00

  • PMH22 CONVENTIONAL ANTIPSYCHOTICS CAN BE COST EFFECTIVE FOR BROADLY DEFINED TREATMENT RESISTANT OR INTOLERANT SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PMH63 TREND AND GEOGRAPHIC VARIATIONS IN THE LENGTH OF STAY FOR SCHIZOPHRENIA IN THE UNITED STATES

    May 1, 2004, 00:00

  • PMH76 A COMPREHENSIVE RETROSPECTIVE STUDY OF ASSOCIATIONS BETWEEN DIABETES AND TREATMENT WITH RISPERIDONE, OLANZAPINE, QUETIAPINE, AND CONVENTIONAL ANTIPSYCHOTICS

    May 1, 2004, 00:00

  • PMD10 TESTING AND CORRECTING NON-RANDOM SELECTION BIAS- AN APPLICATION TO CENSORED MEDICAL COST

    May 1, 2004, 00:00

  • PHP20 FACTORS THAT INFLUENCE PRESCRIBING DECISIONS

    May 1, 2004, 00:00

  • PCN26 ARE HEALTH STATES 'TIMELESS'? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION USING A REPEATED MEASURES DESIGN

    May 1, 2004, 00:00

  • PNL22 THE SENSITIVITY OF COST-EFFECTIVENESS ESTIMATES IN MULTIPLE SCLEROSIS TO INTERNATIONAL DIFFERENCES IN NATURAL HISTORY- SWEDEN VERSUS NOVA SCOTIA, CANADA

    May 1, 2004, 00:00

  • PE4 AN AUTOMATED METHOD TO INFER MORBIDITY DESCRIPTIONS FROM PATIENT PHARMACY PROFILES

    May 1, 2004, 00:00

  • PAA9 ASTHMA-RELATED HEALTH CARE SERVICES UTILIZATION BY AFRICAN-AMERICANS IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PIN8 AN EVIDENCE BASED PROPOSAL TO MODIFY PRESCRIBING PATTERNS-THE CASE OF METRONIDAZOL USED WHEN INTESTINAL AMOEBIASIS IS SUSPECTED

    May 1, 2004, 00:00

  • PES12 ESTIMATE OF DIRECT MEDICAL COSTS ASSOCIATED WITH THE USE OF CONVENTIONAL SYSTEMIC AGENTS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS

    May 1, 2004, 00:00

  • CV1 HEALTH PREFERENCES AFTER CABG OR PCI FOLLOWING AN ACUTE MYOCARDIAL INFARCTION

    May 1, 2004, 00:00

  • PAR1 RHEUMATOID ARTHRITIS IMPACT OF DISEASE AND DRUG THERAPY

    May 1, 2004, 00:00

  • PCV37 HEALTH-RELATED QUALITY OF LIFE OF PATIENTS MAKING AN ATTEMPT AT SMOKING CESSATION

    May 1, 2004, 00:00

  • PMD12 MEDICATION COMPLIANCE AND CONCOMITANT THERAPY

    May 1, 2004, 00:00

  • PCO3 ESTIMATING COST-EFFECTIVENESS OF INHALED CORTICOSTEROIDS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE PRESENCE OF MISSING DATA

    May 1, 2004, 00:00

  • PIN33 UTILIZATION PATTERNS OF MEDICAL SERVICES AND PRESCRIPTION DRUGS FOR THE TREATMENT OF TINEA CAPITIS

    May 1, 2004, 00:00

  • PNL5 COST-EFFECTIVENESS ANALYSIS OF RIZATRIPTAN AND SUMATRIPTAN VERSUS CAFERGOT IN THE ACUTE TREATMENT OF MIGRAINE

    May 1, 2004, 00:00

  • PNL3 PREDICTORS OF LOST PRODUCTIVITY AMONG EMPLOYEES WITH MIGRAINE HEADACHES IN A MEDICAL GROUP SETTING- IMPLICATIONS FOR WORKSITE DISEASE MANAGEMENT PROGRAMS

    May 1, 2004, 00:00

  • PDB17 RETIREE TYPE 2 DIABETES HEALTH CARE COSTS FOR A SELF-INSURED TELECOMMUNICATIONS COMPANY

    May 1, 2004, 00:00

  • HR2 DECISION-MAKERS PERCEPTIONS OF ACCESS TO HIGH COST DRUGS (HCDS) IN PUBLIC HOSPITALS IN AUSTRALIA

    May 1, 2004, 00:00

  • PUK10 USING CONJOINT ANALYSIS TO EXAMINE PATIENT QUALITY OF LIFE AND PRESCRIPTION INSURANCE COVERAGE PREFERENCES IN THE MANAGEMENT OF OVERACTIVE BLADDER

    May 1, 2004, 00:00

  • PAR14 CONTRIBUTION OF PAIN, SITE OF PAIN AND NUMBER OF JOINTS AFFECTED ON PRODUCTIVITY LOSS AMONG WORKERS AND NON-WORKERS WITH OSTEOARTHRITIS

    May 1, 2004, 00:00

  • PHP36 PRESCRIPTION DRUG UTILIZATION PATTERNS AND CHARACTERISTICS FOR A MEDICARE POPULATION IN MANAGED CARE

    May 1, 2004, 00:00

  • PCN28 GAPS IN COLORECTAL CANCER OUTCOMES RESEARCH

    May 1, 2004, 00:00

  • PMH47 WEIGHT GAIN AND IMPROVEMENT IN PSYCHOPATHOLOGY DURING TREATMENT OF SCHIZOPHRENIA WITH ANTIPSYCHOTICS AND WITH PLACEBO

    May 1, 2004, 00:00

  • PCN19 THE COST-EFFECTIVENESS ANALYSIS RECOMBINANT HUMAN ERYTHROPOIETIN GROWTH FACTORS VS. TRANSFUSION IN CHEMOTHERAPY CANCER PATIENTS

    May 1, 2004, 00:00

  • PHP18 PREVALENCE OF DRUG-RELATED PROBLEMS AMONGST HOSPITALISED PATIENTS ON POLYPHARMACY IN SINGAPORE

    May 1, 2004, 00:00

  • PCN5 ANALYSIS OF OVER 2400 MODERN PHASE I CANCER TRIALS- COMPOSITION, OUTCOMES, AND USE OF SURROGATE ENDPOINTS

    May 1, 2004, 00:00

  • PNL9 COST EFFECTIVENESS ANALYSIS OF INTERFERON BETA-1A (AVONEX) IN PRE-CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS)

    May 1, 2004, 00:00

  • PAR11 REVALIDATION OF THE CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) SHORT FORM INSTRUMENT

    May 1, 2004, 00:00

  • PMH14 CANADIAN NETWORK FOR BIPOLAR DISORDER (CAN-BD)- FREQUENCY OF RELAPSE IN AN OBSERVATIONAL STUDY

    May 1, 2004, 00:00

  • PMH23 COST-EFFECTIVENESS EVALUATION OF LONG-ACTING RISPERIDONE INJECTION

    May 1, 2004, 00:00

  • PMH75 DEVELOPMENT OF A PATIENT-REPORTED INSTRUMENT TO ASSESS THE FUNCTIONAL STATUS OF PATIENTS WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PMH71 WHEN BIPOLAR DISORDER IS BEING IDENTIFIED- PHASE OF DISORDER, PROVIDER SPECIALTY, FACILITY TYPE, AND RESOURCE UTILIZATION SURROUNDING THE INITIAL BIPOLAR DIAGNOSIS IN CLINICAL PRACTICE

    May 1, 2004, 00:00

  • PIN11 TESTING AND TREATMENT OF HEPATITIS C IN THE LOUISIANA MEDICAID POPULATION

    May 1, 2004, 00:00

  • PMH6 ANTIPSYCHOTIC TREATMENT AND DIABETES IN A PRIVATELY INSURED POPULATION

    May 1, 2004, 00:00

  • PCV56 DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERTENSION

    May 1, 2004, 00:00

  • PAA7 HEALTH CARE EXPENDITURES OF PATIENTS WITH COMORBID ALLERGIC RHINITIS AND ASTHMA

    May 1, 2004, 00:00

  • PIN14 ECONOMIC COST STRUCTURE OF SEVERE SEPSIS MANAGEMENT

    May 1, 2004, 00:00

  • PMD16 INVESTIGATING THE CEILING EFFECT IN THE EUROQOL IN THE U.S GENERAL POPULATION

    May 1, 2004, 00:00

  • PE2 THE EFFECTS OF ANTIDEPRESSANT DRUGS ON THE RISK OF COLORECTAL CANCER-A POPULATION-BASED CASE-CONTROL STUDY

    May 1, 2004, 00:00

  • PMH13 USING PATIENT REPORTED OUTCOMES (PROS) TO DETERMINE DEPRESSION AND ANXIETY POPULATIONS IN FOUR COUNTRIES

    May 1, 2004, 00:00

  • PDB29 VALIDATION OF THE DIABETES RESOURCE CONSUMPTION INDEX (DRCI)- A RISK ADJUSTMENT TOOL FOR PREDICTING HEALTH CARE RESOURCE USE AND COSTS

    May 1, 2004, 00:00

  • PCV52 IMPACT OF MARKET FORCES ON STATIN PERSISTENCE PATTERS IN A CALIFORNIA MEDICAID POPULATION

    May 1, 2004, 00:00

  • PDB25 PAIN SEVERITY AFFECTS PERCEIVED HEALTH STATUS IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY

    May 1, 2004, 00:00

  • PNL1 HOW COGNITIVE FUNCTION AFFECTS ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ALZHEIMERS DISEASE

    May 1, 2004, 00:00

  • OP1 IS THE CURRENT METHOD OF VALUING HEALTH OUTCOMES IN COST-EFFECTIVENESS ANALYSIS VALID?

    May 1, 2004, 00:00

  • RX4 A DYNAMIC MODEL OF BUDGET IMPACT ANALYSES

    May 1, 2004, 00:00

  • PCV25 TOBACCO COST-EFFECTIVENESS ANALYSES AND THE PAYER- IS THE SHORT TERM LONG OVERDUE?

    May 1, 2004, 00:00

  • PCV50 GASTRIC BYPASS SURGERY-AN OVERVIEW

    May 1, 2004, 00:00

  • PCV45 MECHANICAL AND ALLERGIC ADVERSE EVENTS RELATED TO CENTRAL VASCULAR CATHETERS- EPIDEMIOLOGY IN THE MEDICARE HOSPITALIZED SURGICAL POPULATION, 2002

    May 1, 2004, 00:00

  • PUK5 THE COST-EFFECTIVENESS OF SIROLIMUS WITH CYCLOSPORIN WITHDRAWAL VERSUS LOW DOSE SIROLIMUS AND CONTINUED CYCLOSPORIN WHEN INITIATED WITHIN FOUR MONTHS OF RENAL TRANSPLANTATION

    May 1, 2004, 00:00

  • PNL10 COST-EFFECTIVENESS OF SCREENING FOR NEUTRALIZING ANTIBODIES TO INTERFERON BETAS IN THE TREATMENT OF MULTIPLE SCLEROSIS

    May 1, 2004, 00:00

  • PNL7 A RETROSPECTIVE CLAIMS ANALYSIS OF THE DIRECT COSTS OF MIGRAINE AND ITS COMORBID CONDITIONS IN TAIWAN

    May 1, 2004, 00:00

  • PCV14 A COMPARISON OF THE RISK OF ADVERSE THROMBOEMBOLIC AND BLEEDING EVENTS BETWEEN SUBJECTS TREATED AND NOT TREATED WITH WARFARIN

    May 1, 2004, 00:00

  • RI1 THE EFFECT OF PRESCRIPTION DRUG COVERAGE ON THE COST OF CARE FOR MEDICARE BENEFICIARIES WITH ASTHMA

    May 1, 2004, 00:00

  • PHP40 POST-LAUNCH STUDIES-WHAT IS DESIRABLE, WHAT IS FEASIBLE?

    May 1, 2004, 00:00

  • PHP11 ESTIMATING THE ABILITY-TO-PAY FOR HEALTH CARE EXPENDITURES RISING FASTER THAN GDP- AN INTERNATIONAL PERSPECTIVE COMPARING THE USA AND GERMANY

    May 1, 2004, 00:00

  • PGI12 EVALUATING THE GERD SYMPTOM AND MEDICATION QUESTIONNAIRE (GERD-SMQ) IN A CLINICAL TRIAL

    May 1, 2004, 00:00

  • PGI4 INPATIENT COSTS OF LIVER CIRRHOSIS IN THE UNITED STATES- A RETROSPECTIVE CLAIMS DATA ANALYSIS, 1993-2001

    May 1, 2004, 00:00

  • PGI1 GASTROINTESTINAL ADVERSE EVENTS FROM NON STEROIDAL ANTI-INFLAMMATORY DRUGS- RELATIONSHIPS BETWEEN RISK ASSESSMENT, VETERANS AFFAIRS PRESCRIBING GUIDELINES, AND HOSPITALIZATION COSTS

    May 1, 2004, 00:00

  • PDB12 ESTIMATING THE REDUCTION IN LONG TERM COMPLICATION AND COSTS OF COMPLICATIONS IN TYPE 1 DIABETES BY REDUCED A1C LEVELS DUE TO MORE FREQUENT BLOOD GLUCOSE MONITORING

    May 1, 2004, 00:00

  • PES17 IMPROVED HEALTH-RELATED QUALITY OF LIFE FOLLOWING SUSTAINED REDUCTIONS IN ANTI DS-DNA ANTIBODYS [DSDNA AB] IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AFTER TREATMENT WITH LJP394

    May 1, 2004, 00:00

  • RX1 CLAIM-BASED DRUG WASTAGE ESTIMATION-HOW HIDDEN REFILL BEHAVIOR CAN HELP

    May 1, 2004, 00:00

  • PAR18 RACIAL DISPARITIES IN PRESCRIBING OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS OVER OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN A MEDICAID MANAGED CARE POPULATION

    May 1, 2004, 00:00

  • OP2 COMPARISON OF DISCRETE CHOICE EXPERIMENT (DCE) WITH VISUAL ANALOG SCALING (VAS) METHODS FOR ESTIMATING PREFERENCES FOR PHYSICAL DISABILITY STATES

    May 1, 2004, 00:00

  • PHP22 TRENDS IN APPROVALS BY THE PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE

    May 1, 2004, 00:00

  • PIN2 RETREATMENT RATES OF ACUTE OTITIS MEDIA IN PATIENTS WITH TYMPANOSTOMY TUBES WITHIN THE LOUISIANA MEDICAID PROGRAM

    May 1, 2004, 00:00

  • PCO5 ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A STATE HEALTH INSURANCE PROGRAM

    May 1, 2004, 00:00

  • PES9 ELIGIBILITY, UTILIZATION, AND COSTS IN A CALIFORNIA MEDICAID LUPUS POPULATION

    May 1, 2004, 00:00

  • PMD4 ISHIKAWA CAUSE AND EFFECT DIAGRAMS-A USEFUL TOOL IN DESIGNING ECONOMIC ANALYSES

    May 1, 2004, 00:00

  • PGI9 RESPONSIVENESS TO CHANGE AND ENGLISH LANGUAGE VALIDATION OF THE WPAI-GERD QUESTIONNAIRE-RESULTS FROM A CANADIAN STUDY

    May 1, 2004, 00:00

  • PAA8 THE EFFECT OF HAVING A PRIMARY CARE PROVIDER ON ASTHMA HEALTH CARE EXPENDITURE AND HEALTH CARE UTILIZATION

    May 1, 2004, 00:00

  • PMH69 PATTERNS OF PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PCN16 ECONOMIC BURDEN OF PROSTATE CANCER AMONG HOSPITALIZED PATIENTS

    May 1, 2004, 00:00

  • PHP26 CCOHTA GUIDELINES FOR THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES- CANADA 2004

    May 1, 2004, 00:00

  • PHP39 STOCK MARKET VALUATION AND FIRM-LEVEL DETERMINANTS OF INNOVATIVE ACTIVITY IN THE PHARMACEUTICAL INDUSTRY

    May 1, 2004, 00:00

  • PHP27 INFLATION- PRESCRIPTION DRUG MARKET BASKET DEFINITION AND THEIR IMPACT

    May 1, 2004, 00:00

  • PES11 A COST COMPARISON OF TOPICAL 5% FLUOROURACIL VS. CRYOSURGERY FOR THE TREATMENT OF ACTINIC KERATOSIS

    May 1, 2004, 00:00

  • PAA16 PREDICTORS OF SELF-REPORTED ADHERENCE IN PATIENTS WITH ASTHMA

    May 1, 2004, 00:00

  • PIN28 MEDICOECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF INFANTILE BRONCHIOLITIS IN FRANCE

    May 1, 2004, 00:00

  • PGI2 A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF TOTAL AND PARTIAL LAPAROSCOPIC FUNDOPLICATION FOR THE TREATMENT OF GORD

    May 1, 2004, 00:00

  • PMH12 THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIDEPRESSANT THERAPY IN MAJOR DEPRESSIVE DISORDER

    May 1, 2004, 00:00

  • PHP32 HEALTH-RELATED QUALITY OF LIFE AND HEALTH PREFERENCE AS PREDICTORS OF MORTALITY AMONG OLDER PEOPLE AT VETERAN HOME

    May 1, 2004, 00:00

  • PCV40 ASSESSMENT OF THE QUALITY OF DRUG TREATMENT IN CORONARY ARTERY DISEASE USING QUALITY INDICATORS

    May 1, 2004, 00:00

  • PMH67 DEPRESSION DIAGNOSIS IN PRIMARY CARE VISITS NOT FOR MENTAL HEALTH REASONS

    May 1, 2004, 00:00

  • PHP8 PEER PRESSURE IN HEALTH CARE

    May 1, 2004, 00:00

  • ND1 ESTIMATING COST-EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS USING NET BENEFIT REGRESSION MODEL METHODS

    May 1, 2004, 00:00

  • THE ECONOMIC BURDEN OF TYPE 2 DIABETES MANAGEMENT BY ETHNIC GROUP IN THE TEXAS MEDICAID POPULATION- DB2/PDB19

    May 1, 2004, 00:00

  • PCN27 THE BREAST CANCER SCREENING RATES OF GEORGIA MEDICAID RECIPIENTS

    May 1, 2004, 00:00

  • PMH61 TRENDS IN ANTIPSYCHOTIC PRESCRIBING TO CHILDREN AND ADOLESCENTS- 1996 TO 2001

    May 1, 2004, 00:00

  • PMD2 MONTE-CARLO VALIDATION OF DELTA-K METHOD FOR SAMPLE-SIZE CALCULATION IN A COST-EFFECTIVENESS TRIAL

    May 1, 2004, 00:00

  • PBR3 THE HEALTH-RELATED QUALITY OF LIFE EXPERIENCES OF YOUNG ADULTS WITH SICKLE CELL DISEASE- A QUALITATIVE ASSESSMENT

    May 1, 2004, 00:00

  • PGI5 COST-EFFECTIVENESS OF TREATING ADULTS WITH CHRONIC HEPATITIS C (CHC) AND PERSISTENTLY NORMAL ALANINE AMINOTRANSFERASE (PNALT) WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS)

    May 1, 2004, 00:00

  • PMH60 ANALYSIS OF LONGITUDINAL CLAIMS DATA TO EXAMINE FIRST AND SECOND-LINE USE OF PEMOLINE (CYLERT)

    May 1, 2004, 00:00

  • PHP30 PATIENT SATISFACTION WITH HEALTH CARE SERVICES- IDENTIFYING VOIDS

    May 1, 2004, 00:00

  • PAA3 WEB-ENABLED ASTHMA APPLICATION FOR PERSONALIZED MEDICAL COMMUNICATION WITHIN A MULTI-GROUP PRACTICE SETTING

    May 1, 2004, 00:00

  • PDB11 DIFFERENCES IN HYPOGLYCEMIA EVENT RATES AND ASSOCIATED COST-CONSEQUENCE IN PATIENTS INITIATED ON LONG-ACTING AND INTERMEDIATE-ACTING INSULIN PRODUCTS

    May 1, 2004, 00:00

  • POS2 DIFFERENCES BETWEEN DOCTOR AND PATIENT RECALL OF EVENTS IN AND INVESTIGATIONS FOR OSTEOPOROSIS IN FIVE COUNTRIES

    May 1, 2004, 00:00

  • PCN23 XEROSTOMIA SYMPTOMS- A NEWLY DEVELOPED PATIENT REPORTED OUTCOMES QUESTIONNAIRE

    May 1, 2004, 00:00

  • PMH28 COST-EFFECTIVENESS OF INTERVENTIONS TO IMPROVE PATIENT MEDICATON COMPLIANCE IN MAJOR DEPRESSIVE DISORDER

    May 1, 2004, 00:00

  • PCV32 USE OF ANTILIPEMIC DRUGS IN NATIONAL HEALTH CARE GROUP (NHG), SINGAPORE

    May 1, 2004, 00:00

  • PAA18 THE ASSOCIATION BETWEEN MEASURES OF HEALTH STATE UTILITIES, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA

    May 1, 2004, 00:00

  • PPN5 AN OPIATE RENEWAL CLINIC-A COST EFFECTIVE APPROACH TO REDUCING UNSCHEDULED PATIENT VISITS

    May 1, 2004, 00:00

  • PMH78 IDENTIFICATION OF DEPRESSION IN PATIENTS WITH LOW BACK PAIN- IMPACT OF ELECTRONIC MESSAGING AT THE POINT OF CARE

    May 1, 2004, 00:00

  • PHP13 WHO BENEFITS FROM OVER-THE-COUNTER (OTC) MEDICATION COVERAGE IN A STATE MEDICAID PROGRAM?

    May 1, 2004, 00:00

  • The SCOPE Study- Health-Care Consumption Related to Patients with Chronic Obstructive Pulmonary Disease in France

    Mar 1, 2004, 00:00

  • Cost-Effectiveness Analysis of Interventions to Enhance Mammography Compliance Using Computer Modeling (CAN*TROL)

    Mar 1, 2004, 00:00

  • Seniors with Chronic Health Conditions and Prescription Drugs- Benefits, Wealth, and Health

    Mar 1, 2004, 00:00

  • ISPOR Code of Ethics for Researchers Background Article—Report of the ISPOR Task Force on Code of Ethics for Researchers

    Mar 1, 2004, 00:00

  • ISPOR's “Code of Ethics for Researchers”- Is It Ethical?

    Mar 1, 2004, 00:00

  • Inconsistency in DTCA Practices by Manufacturers- Is It Time to Standardize Print Summaries?

    Mar 1, 2004, 00:00

  • A Computer Simulation Model of the Natural History and Economic Impact of Chronic Obstructive Pulmonary Disease

    Mar 1, 2004, 00:00

  • What Is Next for Pharmacoeconomics and Outcomes Research in Asia?

    Mar 1, 2004, 00:00

  • Resource Utilization and Costs of Stroke Unit Care in Germany

    Mar 1, 2004, 00:00

  • The Impact of Managed Eye Care on Use of Vision Services, Vision Costs, and Patient Satisfaction

    Mar 1, 2004, 00:00

  • Out-of-Pocket Health-Care Expenditures among Older Americans with Cancer

    Mar 1, 2004, 00:00

  • Satisfaction with Medication- An Overview of Conceptual, Methodologic, and Regulatory Issues

    Mar 1, 2004, 00:00

  • Assessment of Health-Related Quality of Life in Children- A Review of Conceptual, Methodological, and Regulatory Issues

    Jan 1, 2004, 00:00

  • A Pharmacoeconomic Evaluation of Seven-Valent Pneumococcal Conjugate Vaccine in Spain

    Jan 1, 2004, 00:00

  • Modeling the Efficiency of Reaching a Target Intermediate End Point- A Case Study in Type 2 Diabetes in the United States

    Jan 1, 2004, 00:00

  • Outcomes Research in Health Care- Simulations to Drive Cost Conclusions

    Jan 1, 2004, 00:00

  • Cost-Effectiveness versus Cost–Utility Analysis of Interventions for Cancer- Does Adjusting for Health-Related Quality of Life Really Matter?

    Jan 1, 2004, 00:00

  • Proposal of Polish Guidelines for Conducting Financial Analysis and Their Comparison to Existing Guidance on Budget Impact in Other Countries

    Jan 1, 2004, 00:00

  • Relationships of Clinical, Psychologic, and Individual Factors with the Functional Status of Neck Pain Patients

    Jan 1, 2004, 00:00

  • A Comprehensive Strategy for the Interpretation of Quality-of-Life Data Based on Existing Methods

    Jan 1, 2004, 00:00

  • The Impact of Olanzapine, Risperidone, or Haloperidol on the Cost of Schizophrenia Care in a Medicaid Population

    Jan 1, 2004, 00:00

  • Using Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome Patients- A Cost–Utility Analysis in Spain

    Jan 1, 2004, 00:00

  • Letter to the Editor

    Jan 1, 2004, 00:00

  • ME4 HOW FREQUENTLYARE ECONOMIC EVALUATIONS USED IN DECISION MAKING?

    Nov 1, 2003, 00:00

  • QL6 PERFORMANCE OF THE EQ-5D IN PATIENTS WITH IRRITABLE BOWEL SYNDROME

    Nov 1, 2003, 00:00

  • PCV52 ECONOMIC ANALYSIS OF THE USE OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT STSEGMENT ELEVATION (ACS) FROM THE RUSSIAN HEALTH CARE SYSTEM PERSPECTIVE

    Nov 1, 2003, 00:00

  • PHL7 COST OF TREATMENT (COT) FOR VENOUS LEG ULCERS IN SWEDEN AND THE UK-ESTIMATES FROM CLINICAL EXPERT PANELS AND MODEL SIMULATIONS

    Nov 1, 2003, 00:00

  • PMH8 PREVALENCE AND MEDICAL CARE COSTS OF ANXIETY DISORDERS IN THE UNITED STATES- A NATIONAL ESTIMATE USING THE MEDICAL EXPENDITURE PANEL SURVEY

    Nov 1, 2003, 00:00

  • PMD4 DIFFERENCES IN PATIENT BURDEN BETWEEN ENDOANAL MRI, DEFECOGRAPHY AND ANORECTAL FUNCTIONAL TESTING FOR PATIENTS WITH FAECAL INCONTINENCE

    Nov 1, 2003, 00:00

  • PSN16 PSORIASIS- IMPACT OF THE TREATMENT ON QUALITY OF LIFE

    Nov 1, 2003, 00:00

  • PHL13 THE USE OF A CONDITION-SPECIFIC QUALITY OF LIFE MEASURE (QUALITY OF LIFE-ASSESSMENT FOR GROWTH HORMONE DEFICIENCY IN ADULTS) IN A GENERAL POPULATION

    Nov 1, 2003, 00:00

  • PCN12 BUDGET IMPACT ANALYSIS OF ANASTROZOLE AS ADJUVANT THERAPY IN THE TREATMENT OF EARLY BREAST CANCER IN THE UK

    Nov 1, 2003, 00:00

  • MH1 COST-EFFECTIVENESS OF ANTIDEPRESSANT THERAPY, COGNITIVE BEHAVIOUR THERAPY AND THEIR COMBINATION FOR PEOPLE WITH BULIMIA NERVOSA IN THE UK

    Nov 1, 2003, 00:00

  • PNM8 ALZHEIMERS DISEASE COST OF TREATMENT STUDY (ADCOT) IN THE UNITED KINGDOM

    Nov 1, 2003, 00:00

  • PCV35 BURDEN OF HYPERCHOLESTEROLEMIA IN GERMANY

    Nov 1, 2003, 00:00

  • ME1 ASSESSING GENERALISABILITY OF COST-EFFECTIVENESS ESTIMATES IN MULTINATIONAL STUDIES- APPLICATION TO A TRIAL OF MOXIFLOXACIN IN COMMUNITY-ACQUIRED PNEUMONIA (CAP)

    Nov 1, 2003, 00:00

  • VV1 RISK ADJUSTMENT AND REFERENCE POINTS

    Nov 1, 2003, 00:00

  • PIN13 COST-EFFECTIVENESS OF VORICONAZOLE COMPARED WITH CONVENTIONAL AMPHOTERICIN B IN FIRST LINE TREATMENT OF INVASIVE ASPERGILLOSIS IN BELGIUM

    Nov 1, 2003, 00:00

  • PIN1 PHARMACEUTICAL MANAGEMENT OF NEWLY HIV DIAGNOSED PATIENTS- RESULTS FROM THE STAR (SCHEMAS THERAPEUTIQUESANTIRETROVIRAUX) COHORT

    Nov 1, 2003, 00:00

  • PMH13 AFFECTIVE PSYCHOSES IN ADOLESCENTS-THE ECONOMIC CONSEQUENCES OF ACUTE CARE HOSPITAL ADMISSIONS OVER THREE YEARS

    Nov 1, 2003, 00:00

  • PUK14 'EFFECT SIZE' OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH CHRONIC ALLOGRAFT NEPHROPATHY AND ANEMIA TREATED WITH RH-EPO

    Nov 1, 2003, 00:00

  • PCV29 USE OF RESOURCES AND COST IMPLICATIONS OF STROKE PROPHYLAXIS WITH WARFARIN FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    Nov 1, 2003, 00:00

  • PCV14 EFFECTIVENESS OF SELF-MEASUREMENT OF BLOOD PRESSURE IN HYPERTENSIVE PATIENTS. DIOAMPA STUDY

    Nov 1, 2003, 00:00

  • PSN6 CHILDRENS ATOPIC DERMATITIS- PHARMACOECONOMIC COST ANALYSIS

    Nov 1, 2003, 00:00

  • PMD26 COST-ASSESSMENT RE-CONSIDERED- THE CASE OF HIP FRACTURE

    Nov 1, 2003, 00:00

  • DB3 COST-EFFECTIVENESS OF ROSIGLITAZONE-METFORMIN COMBINATION IN OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES IN GERMANY

    Nov 1, 2003, 00:00

  • PRP15 DO RESPIRATORY DRUGS REDUCE HOSPITAL ADMISSIONS? AN ECOLOGICAL STUDY CARRIED OUT IN MODENA, ITALY, TO INVESTIGATE DISTRICTS VARIABILITY

    Nov 1, 2003, 00:00

  • PCN21 COMPARISON OF PAIN OUTCOMES AND HRQL USING THE TREATMENT OUTCOMES IN PAIN SURVEY (TOPS) IN CANCER-RELATED PAIN

    Nov 1, 2003, 00:00

  • PCV19 A PROBABILISTIC MODEL TO ASSESS THE COST-EFFECTIVENESS OF A NEW STATIN (ROSUVASTATIN) IN THE UK

    Nov 1, 2003, 00:00

  • PDB5 EVIDENCE-BASED ASSESSMENT OF PATIENTS RISK AND POTENTIAL REGARDING THE LONGTERM COMPLICATIONS OF DIABETES USING A NEW MODEL OF PROGNOSIS IN THE DM PROJECT DIAMART

    Nov 1, 2003, 00:00

  • PDB13 PREDICTORS OF EMERGENCY DEPARTMENT VISITS IN ELDERLY PATIENTS WITH DIABETES

    Nov 1, 2003, 00:00

  • PUK16 LOWER IMPACT ON HEALTH RELATED QUALITY OF LIFE (HRQOL) IN ELDERLY PATIENS STARTING AND AFTER ONE YEAR OF HEMODIALYSIS (HD) THAN IN YOUNGER PATIENS-A PROSPECTIVE STUDY

    Nov 1, 2003, 00:00

  • PAR6 ACUTE GOUTY ARTHRITIS- THE COSTEFFECTIVENESS OF A NEW SELECTIVE COX-2 INHIBITOR (ETORICOXIB) IN THE UK

    Nov 1, 2003, 00:00

  • CE3 INTEGRATED ECONOMIC EVALUATION OF ENFUVIRTIDE (ENF) IN THE US USING A COMBINATION OF COST-EFFECTIVENES ANALYSIS (CEA) AND BUDGET IMPACT ANALYSIS (BIA) TO ENHANCE HEALTH CARE DECISION-MAKING

    Nov 1, 2003, 00:00

  • PCV60 INTRODUCTION OF ROSUVASTATIN WILL ENABLE MORE PATIENTS TO ACHIEVE GUIDELINE LDL-C GOALS WITHIN A FIXED BUDGET IN THE UK

    Nov 1, 2003, 00:00

  • PAE11 ECONOMIC EVALUATION OF LATANOPROST AS FIRST LINE GLAUCOMA THERAPY IN 6 EUROPEAN COUNTRIES

    Nov 1, 2003, 00:00

  • PNM23 INTERNATIONAL USE OF HEALTH STATUS QUESTIONNAIRES IN PARKINSONS DISEASE- TRANSLATION IS NOT ENOUGH

    Nov 1, 2003, 00:00

  • PSN14 QUALITY OF LIFE IN PATIENTS SUFFERING FROM PSORIASIS VULGARIS IN GERMANY-A NON-INTERVENTIONAL SURVEY

    Nov 1, 2003, 00:00

  • PCV53 MANAGEMENT OF THE PRIMARY CARE HYPERCHOLESTEROLEMIC PATIENTS THROUGH A CLINICAL DECISION SUPPORT SYSTEM. OPTIMCARE STUDY REPORT

    Nov 1, 2003, 00:00

  • MH4 CHILDREN WITH ADHD (ATTENTION-DEFICIT/HYPERACTIVITY DISORDER)- HEALTH CARE USE AND SOCIAL BURDEN ON THE FAMILY

    Nov 1, 2003, 00:00

  • PMH20 TREATMENT WITH PSYCHOSTIMULANTS IS ASSOCIATED WITH DECREASED RATES OF SUBSTANCE ABUSE AND IMPROVED SCHOOL OUTCOMES AMONG CHILDREN WITH AD/HD

    Nov 1, 2003, 00:00

  • DB1 ACARBOSE FOR THE PREVENTION OF TYPE II DIABETES IN CANADA- AN ECONOMIC EVALUATION

    Nov 1, 2003, 00:00

  • PAE19 RESEARCH 5134- PREVALENCE AND BURDEN OF BLINDNESS, LOW VISION AND VISUAL IMPAIRMENT IN THE COMMUNITY-A NATIONWIDE SURVEY

    Nov 1, 2003, 00:00

  • MS1 FINANCING PHARMACEUTICAL RD- THE ASSOCIATION WITH SALES

    Nov 1, 2003, 00:00

  • PHL6 TREATMENT OF LEG ULCERS IN SWEDEN STILL DEMANDS LARGE RESOURCES IN SPITE OF IMPROVED MANAGEMENT-THE COST OF ILLNESS (COI) ESTIMATED FROM A PATIENT SURVEY AND PUBLISHED EPIDEMIOLOGICAL STUDIES

    Nov 1, 2003, 00:00

  • PWH6 PATIENT AND PARTNER TREATMENT SATISFACTION SCALE (TSS) IN ERECTILE DYSFUNCTION

    Nov 1, 2003, 00:00

  • PSN3 MANAGEMENT AND SOCIO ECONOMIC IMPACT OF ATOPIC DERMATITIS (AD) IN FRANCE-THE ELIPANEL STUDY

    Nov 1, 2003, 00:00

  • CV4 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING IN THE FRENCH SETTING FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA

    Nov 1, 2003, 00:00

  • PPN4 EPIDEMIOLOGY, CO-MORBIDITY, AND IMPACT ON HEALTH-RELATED QUALITY OF LIFE OF SELF-REPORTED HEADACHE AND MUSCULOSKELETAL PAIN-A GENDER PERSPECTIVE

    Nov 1, 2003, 00:00

  • MD2 THE PARAMETRIC BOOTSTRAP- RECONCILING PARAMETRIC AND NON PARAMETRIC METHODS IN THE ESTIMATION OF CONFIDENCE INTERVALS FOR INCREMENTAL COST-EFFECTIVENESS RATIOS?

    Nov 1, 2003, 00:00

  • PRP6 COST OF ASTHMA EXACERBATION IN THE HOSPITAL SETTING IN SPAIN

    Nov 1, 2003, 00:00

  • PIN9 COST-EFFECTIVENESS OF TWO DIFFERENT VACCINATION STRATEGIES FOR THE PREVENTION OF MENINGOCOCCAL C DISEASE IN PORTUGAL

    Nov 1, 2003, 00:00

  • PPN6 CRITICAL PATHWAY STATUS- A COMPARISON OF PATIENT OUTCOMES

    Nov 1, 2003, 00:00

  • PMD16 UNCERTAINTY AND VALUE OF INFORMATION IN RAPID ECONOMIC EVALUATIONS

    Nov 1, 2003, 00:00

  • CV11 CONTROLRISC STUDY- EVALUATION OF THE MODIFICATION IN CARDIOVASCULAR RISK IN HYPERTENSIVE PATIENTS IN PRIMARY CARE THROUGH PATIENT PERSONALIZED EDUCATION

    Nov 1, 2003, 00:00

  • PCV40 ASSESSMENT OF THE COST OF CARDIOVASCULAR DEATH

    Nov 1, 2003, 00:00

  • PCV45 LONG-TERM COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY COMPARED TO FIBRINOLYSIS IN ACUTE MYOCARDIAL INFARCTION

    Nov 1, 2003, 00:00

  • PCV12 EFFECT OF EPROSARTAN ON PULSE PRESSURE PREDICTIVE FACTORS OF RESPONSE

    Nov 1, 2003, 00:00

  • PCN8 PHARMACO-ECONOMIC ASSESSMENT OF CAPECITABINE ORAL CHEMOTHERAPY VERSUS FUFOL MAYO CLINIC CHEMOTHERAPY IN THE TREATMENT OF COLORECTAL CANCER

    Nov 1, 2003, 00:00

  • PMD33 THE USE OF A SEMI-MARKOV PROCESS MODEL IN COST-EFFECTIVENESS MODELING- THE CASE OF ANTI-EPILEPTIC DRUGS

    Nov 1, 2003, 00:00

  • PMD11 SELF-REPORTED PATIENT EXPERIENCE DATA, PROVIDED TO PHYSICIANS AT THE POINT-OFCARE, OFFER AN IMPORTANT COMPLEMENT TO TRADITIONAL EFFICACY DATA AND ENABLE THE DERIVATION OF PRACTICE-WIDE TREATMENT GUIDELINES

    Nov 1, 2003, 00:00

  • PMH6 PHARMACOUTILIZATION OF ANTIDEPRESSANT DRUGS IN PRIMARY CARE- A LONG-TERM RETROSPECTIVE ANALYSIS OF A LARGE POPULATION

    Nov 1, 2003, 00:00

  • PMD15 THE INTERNATIONAL COSTING SOURCES DATABASE- A TOOL FOR ENSURING CONSISTENT AND RIGOROUS INTERNATIONAL COSTING

    Nov 1, 2003, 00:00

  • PIN7 COSTS OF COMMUNITY-ACQUIRED PNEUMONIA FROM THE HOSPITALS PERSPECTIVE IN GERMANY-A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2003, 00:00

  • PRP11 THE VALIDITY OF THE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE FOR PATIENTS WITH ASTHMA (WPAIASTHMA)- RESULTS FROM A WEB-BASED STUDY

    Nov 1, 2003, 00:00

  • PGS8 COST-MINIMISATION ANALYSIS OF PPI-BASED TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI

    Nov 1, 2003, 00:00

  • PRP18 ANALYSIS OF LONGITUDINAL CHANGES IN QUALITY OF LIFE BEFORE AND AFTER LUNG TRANSPLANTATION USING A MULTI-LEVEL MODEL

    Nov 1, 2003, 00:00

  • PCV8 CHOICE OF FIRST-LINE TREATMENT FOR HYPERTENSION IN THE UK- DOES CURRENT PRIMARY CARE PRACTICE REFLECT BRITISH GUIDELINES?

    Nov 1, 2003, 00:00

  • PSN2 EFFECTIVITY AND SAFETY OF TACALCITOL IN PSORIASIS VULGARIS IN SPANISH PATIENTS

    Nov 1, 2003, 00:00

  • PRP7 A CROSS-SECTIONAL, OBSERVATIONAL STUDY TO ESTABLISH THE RESOURCES AND COSTS ASSOCIATED WITH CONTROLLED AND POORLY CONTROLLED MODERATE TO SEVERE ASTHMA PATIENTS IN THE UK

    Nov 1, 2003, 00:00

  • PDB15 RISK OF CONGESTIVE HEART FAILURE IN TYPE 2 DIABETICS EXPOSED TO PIOGLITAZONE VS INSULIN-A MATCHED COHORT ANALYSIS

    Nov 1, 2003, 00:00

  • PAE6 PREVALENCE AND BURDEN OF BLINDNESS AND LOW VISION IN SUBJECTS LIVING IN INSTITUTIONS- A NATION-WIDE SURVEY

    Nov 1, 2003, 00:00

  • PCV33 THE COST-EFFECTIVENESS OF TARKA IN THE TREATMENT OF HEART FAILURE AFTER MYOCARDIAL INFARCTION IN THE US HEALTH CARE SETTING

    Nov 1, 2003, 00:00

  • PCV76 IS THE MLHF QUESTIONNAIRE VALID FOR INTERNATIONAL MULTICENTRIC STUDIES?

    Nov 1, 2003, 00:00

  • PHL5 HEALTH ECONOMIC ANALYSIS OF A SILVER CONTAINING HYDROACTIVATED FOAM DRESSING IN DELAYED HEALING LEG ULCERS

    Nov 1, 2003, 00:00

  • PCV10 IMPROVED COMPLIANCE AND PERSISTENCE WITH ATORVASTATINE THROUGH A PHARMACY-BASED INTERVENTION

    Nov 1, 2003, 00:00

  • HP3 END STAGE RENAL DISEASE IN FRANCE- PLANNING EVOLUTION OF HEALTH CARE NEEDS USING A MARKOV MODEL

    Nov 1, 2003, 00:00

  • PIN4 CONSUMPTION OF ANTIBIOTICS IN EUROPE- RESULTS OF THE ESAC RETROSPECTIVE DATA COLLECTION

    Nov 1, 2003, 00:00

  • PAE7 VISION IMPAIRMENT AS AN INDEPENDENT RISK FACTOR OF INSTITUTIONALIZATION

    Nov 1, 2003, 00:00

  • PHP25 MECHANISMS AND OUTCOMES OF UTILIZATION REVIEW CONDUCTED AMONG PHIC-ACCREDITED HEALTH CARE FACILITIES IN THE PHILIPPINES

    Nov 1, 2003, 00:00

  • PMD39 DESCRIPTION OF THE PRINCIPLES OF GOOD PRACTICE FOR TRANSLATION AND CULTURAL ADAPTATION OF PRO MEASURES- ISPOR QOLSIG GROUP

    Nov 1, 2003, 00:00

  • MS2 LISTENING TO OUR CONSUMERS- THE PHARMACEUTICAL BRAND LOYALIST

    Nov 1, 2003, 00:00

  • PAE10 COMPARISON OF THE CLINICAL EFFICACY AND COST-EFFECTIVENESS OF LUMIGAN AND XALATAN IN THE TREATMENT OF GLAUCOMA

    Nov 1, 2003, 00:00

  • PAE18 IMPROVEMENT IN VISION TARGETED QUALITY OF LIFE (QOL) AFTER CATARACT SURGERY WITH IMPLANTATION OF ACRYSOF NATURAL INTRAOCULAR LENS (IOL)

    Nov 1, 2003, 00:00

  • PHL3 COST-EFFECTIVENESS OF HAEMOPHILIA TREATMENT- A CROSS-NATIONAL ASSESSMENT

    Nov 1, 2003, 00:00

  • PCV64 COST-EFFECTIVENESS ANALYSIS OF CORONARY REVASCULARISATION TECHNIQUES AVAILABLE FOR THE TREATMENT OF ISCHAEMIC HEART DISEASE

    Nov 1, 2003, 00:00

  • PIN8 PROSPECTIVE STUDY ON ACUTE LOWER RESPIRATORY TRACT INFECTIONS IN GERMAN CHILDREN YOUNGER THAN 3 YEARS (PRI.DE)-ECONOMIC IMPACT OF HOSPITALIZED CASES

    Nov 1, 2003, 00:00

  • PCV1 PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION, ELEVATED TROPONIN T LEVELS AND DIABETES MELLITUS. OUTCOME AT THREE MONTHS

    Nov 1, 2003, 00:00

  • GD4 POTENTIAL HOSPITAL SAVINGS RELATED TO THE ADMINISTRATION OF ESOMEPRAZOLE TABLETS THROUGH GASTRIC TUBES IN PATIENTS CURRENTLY TREATED WITH INJECTABLE PPIS

    Nov 1, 2003, 00:00

  • RX1 PRESCRIPTION DRUG INFORMATION- A SURVEY OF THE GENERAL POPULATION IN SPAIN

    Nov 1, 2003, 00:00

  • PCV30 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN IN GREEK PATIENTS WITH HYPERLIPIDAEMIA

    Nov 1, 2003, 00:00

  • PRP5 COST-EFFECTIVENESS OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION PRODUCT 50/100 MCG TWICE DAILYAND BUDESONIDE 400 MCG TWICE DAILY IN THE TREATMENTOF ADULTS WITH ASTHMA IN CHINA

    Nov 1, 2003, 00:00

  • PMD48 RELATIVE WEIGHTS ASSIGNED TO DRUGS AND BIOLOGICALS- OPPS METHODS AND CONCEPTS

    Nov 1, 2003, 00:00

  • PPN7 THE WILLINGNESS-TO-PAY APPROACH IN THE COST-BENEFIT ANALYSIS- THE TREATMENT OF PATIENTS AFFECTED FROM PAINFUL PATHOLOGY

    Nov 1, 2003, 00:00

  • PMH7 COST EFFECTIVENESS OF PHARMACOLOGICAL TREATMENT VERSUS CARE AS USUAL FOR PANIC DISORDER AND/OR DEPRESSION DRIVEN CHEST PAIN- PRELIMINARY RESULTS OF UNBLINDED DATA

    Nov 1, 2003, 00:00

  • CV9 A HEALTH ECONOMIC EVALUATION OF N-3 POLYUNSATURATED FATTY ACIDS (PUFA) IN THE SECONDARY PREVENTION AFTER MI

    Nov 1, 2003, 00:00

  • PCV78 QUALITY OF LIFE IN CHRONIC PATHOLOGIES IN PRIMARY CARE

    Nov 1, 2003, 00:00

  • PNM24 RIVASTIGMINE IS ASSOCIATED WITH SIGNIFICANTLY LESS CAREGIVER BURDEN THAN DONEPEZIL OR GALANTAMINE

    Nov 1, 2003, 00:00

  • PMD44 ADVANCING RISK ADJUSTMENT FOR SCHIZOPHRENIA

    Nov 1, 2003, 00:00

  • PMH22 PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY- ITALIAN RESULTS

    Nov 1, 2003, 00:00

  • PMD6 DEVELOPMENT OF A WEB-BASED SURVEY TO DETERMINE PRACTICE PATTERNS FOR TREATMENT OF ADVANCED STAGE BREAST CANCER IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2003, 00:00

  • PDB18 THE COMPLICATIONS IMPACT ON DIABETES TYPE 2 DIRECT COSTS IN POLAND

    Nov 1, 2003, 00:00

  • MH3 HOSPITALIZATION RELATED TO ABUSE OF THE ELDERLY WITH DEMENTIA AND OTHER MENTAL HEALTH DISORDERS- RESOURCE USE AND COSTS

    Nov 1, 2003, 00:00

  • PDB19 ADVANCED TOOLS FOR ALLOCATION OF MEDICAL PRODUCTS- ECONOMIC EVALUATION OF THE 'HOMECARE' PROGRAMME

    Nov 1, 2003, 00:00

  • QL2 OUALITY OF LIFE FOLLOWING AORTIC VALVE REPLACEMENT SURGERY

    Nov 1, 2003, 00:00

  • PSN5 THE COST-UTILITY OF CALCIPOTRIOL/BETHAMETHASONE (DOVOBET) OINTMENT IN THE TREATMENT OF PSORIASIS VULGARIS IN THE UNITED KINGDOM

    Nov 1, 2003, 00:00

  • PSN15 DURATION OF PSORIASIS AND QUALITY OF LIFE

    Nov 1, 2003, 00:00

  • PRP14 COST OFFSETS FROM PRESCRIPTION COVERAGE OF AGED PERSONS WITH COPD

    Nov 1, 2003, 00:00

  • CS3 INITIAL INSERTION OF A METAL STENT FOR PALLIATION OF MALIGNANT BILIARY OBSTRUCTION- A COST CONSEQUENCE ANALYSIS FOR ENGLAND, FRANCE AND SWEDEN

    Nov 1, 2003, 00:00

  • PHP21 IMPACT OF PHARMACY INTERVENTIONS ON QUALITY OF HOSPITAL PRESCRIBING- INTERVENTIONS AND COST SAVINGS ASSESSMENT

    Nov 1, 2003, 00:00

  • PCV16 EFFECTIVENESS AND COST-EFFECTIVENESS OF THE AMBULATORY BLOOD PRESSURE MONITORING (ABPM) IN THE DIAGNOSTIC OF HYPERTENSION

    Nov 1, 2003, 00:00

  • PCV42 ECONOMIC ANALYSIS OF THE USE OF CONTRAST MEDIA DURING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE AND SPAIN

    Nov 1, 2003, 00:00

  • PIN32 THE POTENTIAL EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF A NEW COMBINATION VACCINE AGAINST MENINGOCOCCAL B AND C AND PNEUMOCOCCAL INFECTIONS IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PRP17 ESTIMATING HOSPITAL BURDEN DUE TO PNEUMONIA, ASPIRATION, AND ACUTE LUNG FAILURE- DATA FROM THE NATIONAL HOSPITAL DISCHARGE SURVEY (NHDS)

    Nov 1, 2003, 00:00

  • PCV70 A PHARMACOECONOMIC COMPARISON OF UNFRACTIONATED HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN USAGE IN ACUTE CORONARY SYNDROME IN RUSSIA

    Nov 1, 2003, 00:00

  • PMH14 THE BURDEN OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD) IN THE NORDIC COUNTRIES-A LITERATURE REVIEW

    Nov 1, 2003, 00:00

  • PAE9 COST AND EFFECTIVENESS OF BRINZOLAMIDE VERSUS DORZOLAMIDE IN THE TREATMENT OF GLAUCOMA- AN ANALYSIS CONDUCTED USING THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE

    Nov 1, 2003, 00:00

  • CP3 DISCONTINUATION RATES OF PHARMACOLOGICAL TREATMENTS FOR OVERACTIVE BLADDER- COMPARISON OF OXYBUTYNIN IMMEDIATE AND EXTENDED RELEASE IN THE UNITED KINGDOM

    Nov 1, 2003, 00:00

  • PHL11 DEVELOPMENT OF THE HAEMOPHILIA AGEGROUP SPECIFIC QUALITY OF LIFE QUESTIONNAIRE

    Nov 1, 2003, 00:00

  • PHP17 SURVEY ON DRUG VALUE ASSESSMENT AMONG PRESCRIBERS AND PAYERS IN ITALIAN HOSPITALS

    Nov 1, 2003, 00:00

  • PIN2 ASSOCIATION BETWEEN UNSUCCESSFUL INITIAL EMPIRIC ANTIBIOTIC THERAPY AND HEALTH CARE RESOURCE USE AMONG PATIENTS UNDERGOING SURGERY FOR COMMUNITY-ACQUIRED INTRA-ABDOMINAL INFECTIONS IN SPAIN

    Nov 1, 2003, 00:00

  • PNM20 VALIDATION OF SINGAPOREAN ENGLISH AND CHINESE EQ-5D VERSIONS IN PATIENTS WITH PARKINSONS DISEASE

    Nov 1, 2003, 00:00

  • PMD21 LIFE EXPECTANCY AND THE DISCOUNTING OF HEALTH OUTCOMES

    Nov 1, 2003, 00:00

  • PIN36 COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS AMONG PRETERM INFANTS IN POLAND

    Nov 1, 2003, 00:00

  • PAE8 SCORING OF VISUAL FIELD MEASURED THROUGH HUMPHREY PERIMETRY- PRINCIPAL COMPONENT VARIMAX ROTATION FOLLOWED BY CLUSTERING ANALYSIS

    Nov 1, 2003, 00:00

  • PCN18 THE COST OF GEMCITABINE/CISPLATIN COMPARED WITH FOUR OTHER NOVEL CHEMOTHERAPEUTIC AGENTS IN POLAND

    Nov 1, 2003, 00:00

  • PGS9 A COST CONSEQUENCE ANALYSIS OF A NEW ENDOSCOPIC INJECTABLE TREATMENT VERSUS SURGERY IN PATIENTS WITH SEVERE GASTRO ESOPHAGEAL REFLUX DISEASE IN FRANCE

    Nov 1, 2003, 00:00

  • CV7 COST-EFFECTIVENESS OF A NEW ANTITHROMBOTIC AGENT- A COMPARISON ACROSS COUNTRIES OF THROMBOPROPHYLAXIS WITH FONDAPARINUX FOLLOWING MAJOR ORTHOPAEDIC SURGERY

    Nov 1, 2003, 00:00

  • PAR14 THE COST OF OSTEOPOROTIC FRACTURES IN FEMALES IN THE UK- AN EPIDEMIOLOGICAL MODEL

    Nov 1, 2003, 00:00

  • PCV28 ECONOMIC EVALUATION AND SURVIVAL ANALYSIS OF IMMUNO-ADSORPTION IN PATIENTS WITH DILATED CARDIOMYOPATHY

    Nov 1, 2003, 00:00

  • PCV22 ECONOMIC EVALUATION OF FONDAPARINUX COMPARED TO ENOXAPARIN IN VENOUS THROMBOEMBOLISM PREVENTION FOLLOWING HIP FRACTURE SURGERY

    Nov 1, 2003, 00:00

  • PMH3 EVALUATION OF MEDICAL DIAGNOSES FOR TEXAS MEDICAID PATIENTS PRESCRIBED ATYPICAL ANTIPSYCHOTIC MEDICATIONS

    Nov 1, 2003, 00:00

  • PIN21 BUDGET IMPACT ANALYSIS OF UNIVERSAL VARICELLA VACCINATION IN GERMANY

    Nov 1, 2003, 00:00

  • PMD42 LINGUISTIC VALIDATION OF THE QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE (Q-LES-Q) IN 24 LANGUAGES

    Nov 1, 2003, 00:00

  • PCV57 COST EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY IN DIABETIC PATIENTS IN ITALY

    Nov 1, 2003, 00:00

  • PDB17 PREDICTED COSTS AND OUTCOMES FROM REDUCED VIBRATION DETECTION IN PEOPLE WITH DIABETES IN THE UK

    Nov 1, 2003, 00:00

  • PCN7 ORAL VINORELBINE IN THE TREATMENT OF NON SMALL CELL LUNG CANCER

    Nov 1, 2003, 00:00

  • GL5 RESPONSIVENESS TO CHANGE OF THE SHORT FORM (SF)-12 HEALTH STATUS INSTRUMENT IN PATIENTS WITH CEREBROVASCULAR DISEASE

    Nov 1, 2003, 00:00

  • PCV66 ONE BILLION EURO FOR THE TREATMENT WITH CSE-ANTAGONISTS IN GERMANY-WHAT ARE THE RESULTS?

    Nov 1, 2003, 00:00

  • PCN15 COST ANALYSIS OF TREATMENT FOR ADVANCED OR RECURRENT GASTRIC CANCER IN JAPAN- ECONOMIC COMPARISON BETWEEN THE ORAL FLUOROPYRIMIDINE TS-1 AND CONVENTIONAL INTRAVENOUS CHEMOTHERAPY

    Nov 1, 2003, 00:00

  • PMH26 QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS IN SPAIN- ONE-YEAR FOLLOW-UP STUDY. SOHO STUDY

    Nov 1, 2003, 00:00

  • CE1 COST-EFFECTIVENESS MODEL OF RECOMBINANT HUMAN CHORIONIC GONADOTROPIN (R-HCG) VERSUS URINARY HCG (U-HCG) FOR ASSISTED REPRODUCTIVE TECHNIQUES (ART) IN THE USA

    Nov 1, 2003, 00:00

  • PRP8 THE COST-EFFECTIVENESS OF DIFFERENT INHALED COMBINATION THERAPIES IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ASTHMA-A MODELING STUDY FROM HEALTH CARE PAYER PERSPECTIVE IN POLAND

    Nov 1, 2003, 00:00

  • PCV50 COSTS OF THE DIAGNOSIS OF RENAL ARTERY STENOSIS

    Nov 1, 2003, 00:00

  • PSN13 COSTEFFECTIVENESS OF ALEFACEPT IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    Nov 1, 2003, 00:00

  • PIN31 COST-EFFECTIVENESS ANALYSIS OF ONCEDAILY MODIFIED RELEASE CLARITHROMYCIN VERSUS CONVENTIONAL TWICE-DAILY GENERIC CLARITHROMYCIN FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

    Nov 1, 2003, 00:00

  • PCV21 THE COST OF STROKE IN SWEDEN-AN INCIDENCE ESTIMATE

    Nov 1, 2003, 00:00

  • PIN3 ASSOCIATION BETWEEN SKIN TATOOS AND HEPATITIS B OF 1/2000 PRIVATES AT ADISORN FORT HOSPITAL, THAIALND

    Nov 1, 2003, 00:00

  • PGS10 COST OF ILLNESS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN ITALY

    Nov 1, 2003, 00:00

  • CS1 A MARKOV MODELLED PHARMACOECONOMIC ANALYSIS OF BIMATOPROST 0.03% (LUMIGAN) IN THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION AS AN ALTERNATIVE TO FILTRATION SURGERY IN ITALY

    Nov 1, 2003, 00:00

  • CP2 DETERMINANTS OF NON ADHERENCE TO ANTIHYPERTENSIVE DRUG TREATMENT

    Nov 1, 2003, 00:00

  • PCV25 THE COST AND THE MANAGEMENT OF THE ACUTE PHASE OF MYOCARDIAL INFARCTION AND STROKE IN HUNGARY

    Nov 1, 2003, 00:00

  • PMD12 COST SOURCE AND PERSPECTIVE IN ECONOMIC OUTCOMES STUDIES- FOCUS ON POSTERS PRESENTED AT THE 7TH ANNUAL INTERNATIONAL ISPOR MEETING

    Nov 1, 2003, 00:00

  • PCV31 ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF ATHEROTHROMBOTIC EVENTS IN HUNGARY

    Nov 1, 2003, 00:00

  • PNM14 SOCIO-ECONOMIC IMPACT OF EPILEPSY ON PARENTS- THE TRILOGY STUDY

    Nov 1, 2003, 00:00

  • PCV43 AN EVALUATION OF THE COSTS ASSOCIATED WITH ACUTE MI TREATMENT IN AND OUT OF HOSPITALS IN GREECE

    Nov 1, 2003, 00:00

  • PHP33 EVALUATION AND SELECTION OF MEDICAL HEALTH TECHNOLOGIES- A GROUP DECISION SUPPORT SYSTEM (GDSS)

    Nov 1, 2003, 00:00

  • PMD31 DECISION-ANALYTIC MODELING IN PARKINSONS DISEASE

    Nov 1, 2003, 00:00

  • PHP10 HOSPITALIZATIONS FOR INJURIES RESULTING FROM CONTACT SPORTS- RESOURCE USE AND COSTS

    Nov 1, 2003, 00:00

  • CV12 A COST-EFFECTIVENESS ANALYSIS OF ACE INHIBITOR TRANDOLAPRIL AS A PREVENTATIVE TREATMENT OF HEART-FAILURE PROGRESSION

    Nov 1, 2003, 00:00

  • PDB12 TYPE-2 DIABETES AND HOSPITAL COSTS ACCORDING TO OBESITY- A RETROSPECTIVE ANALYSIS FROM A HOSPITAL DATA BASE IN FRANCE

    Nov 1, 2003, 00:00

  • PIN19 ECONOMIC IMPACT OF ANTIRETROVIRAL DRUG PRICE REDUCTIONS IN NINE LATIN AMERICAN COUNTRIES

    Nov 1, 2003, 00:00

  • HP1 A PROBLEM SHARED IS A PROBLEM HALVED? COST ACCEPTABILITY OF SHARED CARE VS HOSPITAL TREATMENT

    Nov 1, 2003, 00:00

  • GD3 COSTS OF GASTROENTERITIS IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PAR13 UTILITY VALUATION FROM THE PATIENT PERSPECTIVE OF TREATMENT OUTCOMES IN OSTEOARTHRITIS

    Nov 1, 2003, 00:00

  • GL4 A RANDOMIZED TRIAL OF MEDICAL CO-PRESCRIPTION OF HEROIN TO CHRONIC, TREATMENT-RESISTANT HEROIN ADDICTS IN THE NETHERLANDS- DATA ON QALYS

    Nov 1, 2003, 00:00

  • PCV38 COST-EFFECTIVENESS OF TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR RISK PATIENTS-AN ECONOMIC EVALUATION BASED ON THE HEART PROTECTION STUDY

    Nov 1, 2003, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165 (current)
  • 166
  • 167
  • 168
  • 169
  • 170
  • »